HK1248698A1 - 作为胆碱能毒蕈碱m1受体调节剂的2，3-二氢-4h-1，3-苯并恶嗪-4-酮衍生物 - Google Patents
作为胆碱能毒蕈碱m1受体调节剂的2，3-二氢-4h-1，3-苯并恶嗪-4-酮衍生物 Download PDFInfo
- Publication number
- HK1248698A1 HK1248698A1 HK18108309.9A HK18108309A HK1248698A1 HK 1248698 A1 HK1248698 A1 HK 1248698A1 HK 18108309 A HK18108309 A HK 18108309A HK 1248698 A1 HK1248698 A1 HK 1248698A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- benzoxazin
- modulators
- dihydro
- receptor
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015129043 | 2015-06-26 | ||
| JP2015129043 | 2015-06-26 | ||
| JP2015206797 | 2015-10-20 | ||
| JP2015206797 | 2015-10-20 | ||
| PCT/JP2016/069189 WO2016208775A1 (en) | 2015-06-26 | 2016-06-23 | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1248698A1 true HK1248698A1 (zh) | 2018-10-19 |
Family
ID=56799518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18108309.9A HK1248698A1 (zh) | 2015-06-26 | 2016-06-23 | 作为胆碱能毒蕈碱m1受体调节剂的2，3-二氢-4h-1，3-苯并恶嗪-4-酮衍生物 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9878989B2 (enExample) |
| EP (1) | EP3313836B1 (enExample) |
| JP (1) | JP6745824B2 (enExample) |
| KR (1) | KR20180019234A (enExample) |
| CN (1) | CN107922403A (enExample) |
| AU (1) | AU2016284654B9 (enExample) |
| CA (1) | CA2988572A1 (enExample) |
| CL (1) | CL2017003127A1 (enExample) |
| CO (1) | CO2017012859A2 (enExample) |
| CR (1) | CR20170568A (enExample) |
| DO (1) | DOP2017000309A (enExample) |
| EA (1) | EA201890152A1 (enExample) |
| HK (1) | HK1248698A1 (enExample) |
| IL (1) | IL256059A (enExample) |
| MX (1) | MX2017016875A (enExample) |
| PE (1) | PE20180500A1 (enExample) |
| PH (1) | PH12017502351A1 (enExample) |
| TN (1) | TN2017000508A1 (enExample) |
| TW (1) | TW201710255A (enExample) |
| UA (1) | UA121503C2 (enExample) |
| UY (1) | UY36750A (enExample) |
| WO (1) | WO2016208775A1 (enExample) |
| ZA (1) | ZA201708387B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016206101A1 (en) | 2015-06-26 | 2016-12-29 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| EP3313836B1 (en) * | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6860551B2 (ja) | 2016-03-11 | 2021-04-14 | 武田薬品工業株式会社 | 芳香環化合物 |
| WO2018159639A1 (ja) * | 2017-02-28 | 2018-09-07 | 武田薬品工業株式会社 | 複素環化合物の製造方法 |
| WO2018194181A1 (en) | 2017-04-18 | 2018-10-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
| WO2018212312A1 (ja) | 2017-05-19 | 2018-11-22 | 武田薬品工業株式会社 | スクリーニング方法 |
| AU2018289939B2 (en) | 2017-06-20 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| PT3643718T (pt) | 2017-06-20 | 2023-10-26 | Takeda Pharmaceuticals Co | Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1 |
| EP3858838A4 (en) * | 2018-09-28 | 2022-06-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7443238B2 (ja) * | 2018-09-28 | 2024-03-05 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7446232B2 (ja) | 2018-09-28 | 2024-03-08 | 武田薬品工業株式会社 | 縮合環化合物 |
| KR102288434B1 (ko) * | 2018-10-18 | 2021-08-12 | 에이치케이이노엔 주식회사 | 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도 |
| US11999716B2 (en) | 2018-10-24 | 2024-06-04 | Vanderbilt University | WDR5 inhibitors and modulators |
| WO2020247679A1 (en) * | 2019-06-04 | 2020-12-10 | Vanderbilt University | Wdr5 inhibitors and modulators |
| CN114539035B (zh) * | 2021-03-10 | 2023-08-18 | 山东新时代药业有限公司 | 一种七氟烷的合成方法 |
| WO2025231260A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2025231259A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| CZ281628B6 (cs) | 1991-07-29 | 1996-11-13 | Warner-Lambert Company | Deriváty chinazolinu a farmaceutické přípravky na jejich bázi |
| IT1255179B (it) | 1992-06-26 | 1995-10-20 | Enzo Cereda | Azaciclo e azabiciclo alchiliden idrossilamine |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| WO1998030243A1 (en) | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| CA2317942A1 (en) * | 1998-01-16 | 1999-07-22 | Purdue Research Foundation | Alkenyldiarylmethane non-nucleoside hiv-1 reverse transcriptase inhibitors |
| IL137517A0 (en) | 1998-01-27 | 2001-07-24 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl factor xa inhibitors |
| WO2000032590A1 (en) | 1998-11-25 | 2000-06-08 | Aventis Pharmaceuticals Products Inc. | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
| HUP0203375A3 (en) | 1999-07-28 | 2005-03-29 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl compounds |
| JP2001131173A (ja) | 1999-08-23 | 2001-05-15 | Kyorin Pharmaceut Co Ltd | 二環式複素環誘導体 |
| JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| EP1316203A2 (en) | 2000-06-30 | 2003-06-04 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| JP2004532200A (ja) | 2001-03-15 | 2004-10-21 | サエジス ファーマシューティカルズ， インコーポレイテッド | 全身性ストレスの後に認識機能を回復するための方法 |
| US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| US20030004913A1 (en) | 2001-07-02 | 2003-01-02 | Koninklijke Philips Electronics N.V. | Vision-based method and apparatus for detecting an event requiring assistance or documentation |
| EP1448537A4 (en) | 2001-11-26 | 2005-05-04 | Cortex Pharma Inc | CARBONYLBENZOXAZINIC COMPOUNDS ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES |
| US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| US20060233843A1 (en) | 2003-02-19 | 2006-10-19 | Conn P J | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| EP1613321A2 (en) | 2003-03-28 | 2006-01-11 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
| US20040266659A1 (en) | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
| GB0504019D0 (en) | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
| EP1885708A2 (en) | 2005-04-15 | 2008-02-13 | Board of Trustees of Michigan State University | Gpcr modulators |
| GB0516570D0 (en) | 2005-08-12 | 2005-09-21 | Astrazeneca Ab | Amide derivatives |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| WO2007044937A2 (en) | 2005-10-13 | 2007-04-19 | President And Fellows Of Harvard College | Compositions and methods to modulate memory |
| UA98297C2 (en) | 2005-12-21 | 2012-05-10 | Янссен Фармацевтика, Н.В. | Triazolopyridazines as tyrosine kinase modulators |
| GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US7834023B2 (en) | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
| AP2502A (en) | 2007-01-03 | 2012-10-23 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses |
| US8618074B2 (en) | 2007-03-15 | 2013-12-31 | Board Of Regents Of The University Of Texas System | GPCR enhanced neuroprotection to treat brain injury |
| CN101821252A (zh) | 2007-08-29 | 2010-09-01 | 先灵公司 | 取代的吲哚衍生物及其使用方法 |
| TW200924751A (en) | 2007-08-29 | 2009-06-16 | Schering Corp | 2,3-substituted indole derivatives and methods of use thereof |
| KR20100065167A (ko) | 2007-08-29 | 2010-06-15 | 쉐링 코포레이션 | 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체 |
| CA2700332A1 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2009039460A2 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | Co-administration of pimavanserin with other agents |
| US8765757B2 (en) | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| MX2010005355A (es) | 2007-11-16 | 2010-06-02 | Schering Corp | Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos. |
| US20110024198A1 (en) | 2008-02-19 | 2011-02-03 | Baker Hughes Incorporated | Bearing systems containing diamond enhanced materials and downhole applications for same |
| WO2010042603A1 (en) | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
| JP5102397B2 (ja) | 2008-11-20 | 2012-12-19 | メルク・シャープ・エンド・ドーム・コーポレイション | アリールメチルベンゾキナゾリノンｍ１レセプターポジティブアロステリックモジュレーター |
| WO2010096338A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
| SG174220A1 (en) | 2009-03-05 | 2011-10-28 | Mithridion Inc | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| WO2010123716A1 (en) | 2009-04-20 | 2010-10-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
| ES2353093B1 (es) | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
| CA2804215C (en) | 2009-07-22 | 2019-10-01 | Eric Elenko | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| NZ598462A (en) | 2009-08-31 | 2012-12-21 | Merck Sharp & Dohme | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| EP2490692B1 (en) | 2009-10-21 | 2016-11-16 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| EP2512245B1 (en) | 2009-12-14 | 2014-07-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| EP2515656B1 (en) | 2009-12-21 | 2014-08-06 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
| WO2011159553A1 (en) | 2010-06-15 | 2011-12-22 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| WO2012003147A1 (en) | 2010-07-01 | 2012-01-05 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| WO2012047702A1 (en) | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
| US9549928B2 (en) | 2011-04-29 | 2017-01-24 | The University Of Toledo | Muscarinic agonists as enhancers of cognitive flexibility |
| EP2709624B1 (en) * | 2011-05-17 | 2016-04-27 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
| WO2012170599A1 (en) | 2011-06-10 | 2012-12-13 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| US9403802B2 (en) | 2012-03-02 | 2016-08-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use therefor |
| EA028382B1 (ru) | 2012-03-23 | 2017-11-30 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
| JP6075408B2 (ja) | 2012-11-22 | 2017-02-08 | 株式会社デンソー | 物標検出装置 |
| CA2886139A1 (en) | 2012-12-27 | 2014-07-03 | F. Hoffmann-La Roche Ag | Comt inhibitors |
| JP6402115B2 (ja) | 2013-02-04 | 2018-10-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体 |
| KR101819567B1 (ko) | 2013-05-06 | 2018-02-28 | 가천대학교 산학협력단 | 혈관신생-매개된 질환의 치료용 화합물 |
| JP6063400B2 (ja) | 2014-01-08 | 2017-01-18 | 株式会社日立ビルシステム | エレベータの異常監視装置 |
| EA030373B1 (ru) | 2014-04-23 | 2018-07-31 | Такеда Фармасьютикал Компани Лимитед | Изоиндолин-1-оновые производные в качестве положительных аллостерических модуляторов холинергического мускаринового m1 рецептора для лечения болезни альцгеймера |
| US10208046B2 (en) | 2014-05-16 | 2019-02-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| US10214508B2 (en) | 2014-06-13 | 2019-02-26 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| EP3313836B1 (en) * | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6860551B2 (ja) | 2016-03-11 | 2021-04-14 | 武田薬品工業株式会社 | 芳香環化合物 |
| WO2018122845A1 (en) | 2016-12-29 | 2018-07-05 | Rvx Therapeutics Ltd. | Methods and compositions for potentiating cns drugs and reducing their side effects |
-
2016
- 2016-06-23 EP EP16756814.6A patent/EP3313836B1/en active Active
- 2016-06-23 WO PCT/JP2016/069189 patent/WO2016208775A1/en not_active Ceased
- 2016-06-23 EA EA201890152A patent/EA201890152A1/ru unknown
- 2016-06-23 CR CR20170568A patent/CR20170568A/es unknown
- 2016-06-23 KR KR1020187002502A patent/KR20180019234A/ko not_active Withdrawn
- 2016-06-23 UY UY0001036750A patent/UY36750A/es not_active Application Discontinuation
- 2016-06-23 AU AU2016284654A patent/AU2016284654B9/en not_active Ceased
- 2016-06-23 UA UAA201800653A patent/UA121503C2/uk unknown
- 2016-06-23 TW TW105119717A patent/TW201710255A/zh unknown
- 2016-06-23 HK HK18108309.9A patent/HK1248698A1/zh unknown
- 2016-06-23 US US15/190,642 patent/US9878989B2/en active Active
- 2016-06-23 MX MX2017016875A patent/MX2017016875A/es unknown
- 2016-06-23 PE PE2017002792A patent/PE20180500A1/es unknown
- 2016-06-23 TN TNP/2017/000508A patent/TN2017000508A1/en unknown
- 2016-06-23 JP JP2017567489A patent/JP6745824B2/ja active Active
- 2016-06-23 US US15/735,418 patent/US10323027B2/en active Active
- 2016-06-23 CA CA2988572A patent/CA2988572A1/en not_active Abandoned
- 2016-06-23 CN CN201680048681.6A patent/CN107922403A/zh active Pending
-
2017
- 2017-10-31 US US15/799,379 patent/US10087150B2/en active Active
- 2017-12-03 IL IL256059A patent/IL256059A/en unknown
- 2017-12-07 CL CL2017003127A patent/CL2017003127A1/es unknown
- 2017-12-11 ZA ZA2017/08387A patent/ZA201708387B/en unknown
- 2017-12-14 CO CONC2017/0012859A patent/CO2017012859A2/es unknown
- 2017-12-18 PH PH12017502351A patent/PH12017502351A1/en unknown
- 2017-12-26 DO DO2017000309A patent/DOP2017000309A/es unknown
-
2018
- 2018-08-27 US US16/113,635 patent/US10428056B2/en active Active
-
2019
- 2019-04-25 US US16/394,762 patent/US10899752B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1248698A1 (zh) | 作为胆碱能毒蕈碱m1受体调节剂的2，3-二氢-4h-1，3-苯并恶嗪-4-酮衍生物 | |
| EP3092207A4 (en) | High aspect boron nitride, methods, and composition containing the same | |
| EP3411614A4 (en) | TURNING CONNECTION WITH SPREADING RING | |
| DK3536324T3 (da) | 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 | |
| EP3210663A4 (en) | Organic silicon composition, and preparation and use thereof | |
| WO2015168225A3 (en) | Alkoxy polycarbonates, bisphenol monomers and methods of making and using the same | |
| LT3402782T (lt) | 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai | |
| IL260495B (en) | History of 3-(carboxyethyl)-8-amino-2-oxo-3,1-diaza-spiro-[5.4]-decane | |
| ZA201602890B (en) | Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators | |
| EP3121202A4 (en) | Copolymer having adjustable glass transition temperature, which is useful as organic electro-optic polymer, and organic electro-optic element using said copolymer | |
| EP3521414A4 (en) | DEXYLARIA GRAMMICA STRAIN | |
| EP3420461A4 (en) | COMMUNICATION WITH TWO SLAVES OR MORE | |
| EP3422454A4 (en) | BIPOLAR BATTERY | |
| EP3233070A4 (en) | Ras-inhibiting indenyl acetamide compounds, compositions, and uses | |
| EP3563455A4 (en) | INTEGRATED DIGITAL LASER | |
| EP3437060A4 (en) | RULE-BASED HIERARCHIC CONFIGURATION | |
| EP3515545A4 (en) | SHARED MICROVALVE | |
| EP3191541A4 (en) | Cationically curable benzoxazine compositions | |
| Sonbert | Alfred Hitchcock, Master of Morality | |
| EP3521357A4 (en) | MODIFICATION AGENTS FOR RESIN AND RESIN COMPOSITION WITH USE THEREOF | |
| EP3286873A4 (en) | Text encryption | |
| AU2016901373A0 (en) | Ubiquinone Compositions, and Methods Relating Thereto | |
| AU2016902636A0 (en) | Burneez, waterless first Aid treatment for minor burns. | |
| HK40007612A (en) | Immunogenic composition | |
| AU2016904822A0 (en) | Clear Fount |